FNY Managed Accounts’s Palvella Therapeutics PVLA Stock Holding History

FNY Managed Accounts’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11	Closed	-$6K	–	879
2017 Q4	$6K	Buy	+11	New	+$5.11K	0.01%	297

Other funds holding PVLA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

FNY Managed Accounts's PVLA Position: Q1 2018 in Review

FNY Managed Accounts sold out of Palvella Therapeutics (PVLA) in Q1 2018, closing a stake of 11 shares — an estimated $6K sold.

FNY Managed Accounts first reported a position in PVLA in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 115 funds tracked by Wall St. Rank hold PVLA as of Q1 2018.

FNY Managed Accounts reported no remaining Palvella Therapeutics position as of Q1 2018 after selling out during the quarter.
FNY Managed Accounts sold 11 Palvella Therapeutics shares in Q1 2018, an estimated $6K.
FNY Managed Accounts first reported a position in Palvella Therapeutics in Q4 2017 and held it in 1 quarter.
FNY Managed Accounts's Palvella Therapeutics position peaked at $6K in Q4 2017.
115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.